The Hematology and Oncology Division supports and facilitates research for new treatments and cures. Our researchers are nationally and internationally known for their areas of expertise. Our research studies include both basic science research and physician-investigator clinical trials.
One group of our basic and clinician scientists focuses on the carcinogenic role of the Wnt signaling pathway in breast, prostate and esophageal carcinomas. Other basic researchers and clinician scientists are collaborating to conduct groundbreaking research on biomarker-based risk assessment and prevention of breast cancer and the development of breast tissue biomarkers to assess efficacy in Phase II breast cancer prevention trials. This group also conducts Phase II drug and behavioral prevention and survivorship clinical trials in patients who have been treated for breast cancer. Another researcher is evaluating the role of soy isoflavones and herbal supplements to prevent prostate cancer.
The clinical trial program is very active with numerous investigator-initiated clinical trials. These trials evaluate novel agents and therapeutic strategies in efforts to improve the treatment of all types of malignancies; to improve the results of allogeneic and autologous stem cell transplantation. Our clinical investigators are leaders in the development of many Phase II and III cooperative group clinical trials; some have led to changes in practice and the standard of care of several malignancies. View these clinical trials by either visiting: